But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

Merck (MRK)’s stock surged by 41%, driven not significantly by revenue but rather by increased profits and heightened ...

What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line. Earnings of $2.13 per ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar ...

Investing.com -- Merck shares received an upgrade at Wells Fargo, with analyst Mohit Bansa lifting the stock to Overweight ...

Merck's two most important growth drivers are encountering headwinds now. While they are manageable, the company's mid-term prospects aren't strong. Merck's biggest growth drivers are cancer drug ...